Anti-GITR antibodies and methods of use thereof
US10280226B2 · kind B2 · utility
14Cited by
66References
30Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Oct 30, 2018 |
| Grant date | May 7, 2019 |
| Priority date | — |
| Expiry date | Oct 30, 2038 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure provides antibodies that specifically bind to human glucocorticoid-induced TNFR family related receptor (GITR) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human GITR and modulate GITR activity, e.g., enhance, activate or induce GITR activity, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as cancer and infectious diseases, by administering an antibody that specifically binds to human GITR and modulates GITR activity e.g., enhances, activates or induces GITR activity.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.